Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy

Clinical Genitourinary Cancer

Volumn 10, Issue 2, 2012, Pages 77-83

  Saylor, Philip J ^a   Escudier, Bernard ^b   Michaelson, M Dror ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Cell signaling; Renal cell carcinoma; Vascular endothelial growth factor receptor

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BRIVANIB; BRIVANIB ALANINATE; CEDIRANIB; DOVITINIB; ENZASTAURIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; INTERFERON; LENVATINIB; LINIFANIB; MASITINIB; MITOGEN ACTIVATED PROTEIN KINASE; NINTEDANIB; ORANTINIB; PAZOPANIB; PROTEIN KINASE C; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VANDETANIB; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; HUMAN; KIDNEY CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR CROSS-TALK; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84862088276     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.01.010     Document Type: Review

References (79)

1. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286 (Pubitemid 46505878)
2. B.I. Rini, M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol 10 2009 992 1000
3. G. Bergers, D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
4. L. Zhang, M. Bhasin, R. Schor-Bardach Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression PLoS ONE 6 2011 e19144
5. N.T. Fernando, M. Koch, C. Rothrock Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors Clin Cancer Res 14 2008 1529 1539 (Pubitemid 351413938)
6. J.A. Abraham, A. Mergia, J.L. Whang Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor Science 233 1986 545 548 (Pubitemid 16019907)
7. J. Folkman, E. Merler, C. Abernathy Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 1971 275 288
8. T. Maciag, T. Mehlman, R. Friesel Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain Science 225 1984 932 935 (Pubitemid 14064174)
9. N. Itoh, D.M. Ornitz Evolution of the Fgf and Fgfr gene families Trends Genet 20 2004 563 569 (Pubitemid 39314564)
10. S. Abuharbeid, F. Czubayko, A. Aigner The fibroblast growth factor-binding protein FGF-BP Int J Biochem Cell Biol 38 2006 1463 1468 (Pubitemid 43729304)
11. N. Turner, R. Grose Fibroblast growth factor signalling: from development to cancer Nat Rev Cancer 10 2010 116 129
12. M. Korc, R.E. Friesel The role of fibroblast growth factors in tumor growth Curr Cancer Drug Targets 9 2009 639 651
13. S. Javerzat, P. Auguste, A. Bikfalvi The role of fibroblast growth factors in vascular development Trends Mol Med 8 2002 483 489
14. S. Werner, H. Smola, X. Liao The function of KGF in morphogenesis of epithelium and reepithelialization of wounds Science 266 1994 819 822 (Pubitemid 24359294)
15. S.H. Lee, D.J. Schloss, J.L. Swain Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor J Biol Chem 275 2000 33679 33687
16. P. Dell'Era, M. Belleri, H. Stabile Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells Oncogene 20 2001 2655 2663 (Pubitemid 32525296)
17. Y. Wang, D. Becker Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth Nat Med 3 1997 887 893 (Pubitemid 27353449)
18. M.J. Birrer, M.E. Johnson, K. Hao Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas J Clin Oncol 25 2007 2281 2287 (Pubitemid 46954656)
19. M. Presta, P. Dell'Era, S. Mitola Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis Cytokine Growth Factor Rev 16 2005 159 178 (Pubitemid 40616114)
20. P.A. Underwood, P.A. Bean, J.R. Gamble Rate of endothelial expansion is controlled by cell:cell adhesion Int J Biochem Cell Biol 34 2002 55 69 (Pubitemid 33152914)
21. I. El-Hariry, M. Pignatelli, N.R. Lemoine FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines Br J Cancer 84 2001 1656 1663 (Pubitemid 32612498)
22. S. Klein, F.G. Giancotti, M. Presta Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells Mol Biol Cell 4 1993 973 982 (Pubitemid 23331537)
23. Y. Sato, T. Shimada, R. Takaki Autocrinological role of basic fibroblast growth factor on tube formation of vascular endothelial cells in vitro Biochem Biophys Res Commun 180 1991 1098 1102
24. S. Kanda, Y. Miyata, H. Kanetake Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1: possible involvement of c-Akt J Biol Chem 279 2004 4007 4016 (Pubitemid 38198983)
25. E. Tassi, A. Wellstein The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma Semin Oncol 33 2006 S50 S56
26. C. Gabler, A. Plath-Gabler, G.J. Killian Expression pattern of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) system members in bovine corpus luteum endothelial cells during treatment with FGF-2, VEGF or oestradiol Reprod Domest Anim 39 2004 321 327 (Pubitemid 39348367)
27. G. Seghezzi, S. Patel, C.J. Ren Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis J Cell Biol 141 1998 1659 1673 (Pubitemid 28309179)
28. S. Tsunoda, T. Nakamura, H. Sakurai Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization Cancer Sci 98 2007 541 548 (Pubitemid 46562745)
29. R. Giavazzi, B. Sennino, D. Coltrini Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis Am J Pathol 162 2003 1913 1926 (Pubitemid 36613049)
30. J.C. Tille, J. Wood, S.J. Mandriota Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro J Pharmacol Exp Ther 299 2001 1073 1085 (Pubitemid 33104979)
31. P. Auguste, D.B. Gürsel, S. Lemière Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms Cancer Res 61 2001 1717 1726 (Pubitemid 34292610)
32. F. Latif, K. Tory, J. Gnarra Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1993 1317 1320 (Pubitemid 23231974)
33. S.C. Clifford, A.H. Prowse, N.A. Affara Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis Genes Chromosomes Cancer 22 1998 200 209 (Pubitemid 28262196)
34. N. de Paulsen, A. Brychzy, M.C. Fournier Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis Proc Natl Acad Sci U S A 98 2001 1387 1392 (Pubitemid 32165508)
35. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
36. C.N. Sternberg, I.D. Davis, J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
37. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
38. M.J. Ratain, T. Eisen, W.M. Stadler Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 2505 2512 (Pubitemid 46630627)
39. B. Escudier, T. Eisen, W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
40. J.C. Yang, L. Haworth, R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434 (Pubitemid 36910021)
41. B. Escudier, A. Pluzanska, P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
42. B.I. Rini, S. Halabi, J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
43. B.I. Rini, J.A. Garcia, M.M. Cooney Toxicity of sunitinib plus bevacizumab in renal cell carcinoma J Clin Oncol 28 2010 e284 e285 Author reply:e286-7
44. S. Négrier, G. Gravis, D. Pérol Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial Lancet Oncol 12 2011 673 680
45. J.A. Garcia, T.E. Hutson, P. Elson Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
46. B.I. Rini, G. Wilding, G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
47. B.I. Rini, B. Escudier, P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
48. B.I. Rini, M.D. Michaelson, J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748
49. R.J. Motzer, B. Escudier, S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
50. L. Wood, R.M. Bukowski, R. Dreicer Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy J Clin Oncol 26 suppl 2008 abstract 16067 www.asco.org Accessed: February 7, 2012
51. M.J. Mackenzie, B.I. Rini, P. Elson Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2011 145 148
52. M.M. Vickers, T.K. Choueiri, M. Rogers Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Urology 76 2010 430 434
53. E. Angevin, V. Grünwald, A. Ravaud A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC) J Clin Oncol 29 suppl 2011 abstract 4551 www.asco.org Accessed: February 7, 2012
54. O. Casanovas, D.J. Hicklin, G. Bergers Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)
55. M. Paez-Ribes, E. Allen, J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
56. E. Allen, I.B. Walters, D. Hanahan Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition Clin Cancer Res 17 2011 5299 5310
57. E. De Falco, D. Porcelli, A.R. Torella SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells Blood 104 2004 3472 3482 (Pubitemid 39564415)
58. D.J. Ceradini, A.R. Kulkarni, M.J. Callaghan Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 Nat Med 10 2004 858 864 (Pubitemid 39070860)
59. D.C. Darland, L.J. Massingham, S.R. Smith Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival Dev Biol 264 2003 275 288 (Pubitemid 37393463)
60. K.K. Hirschi, P.A. D'Amore Control of angiogenesis by the pericyte: molecular mechanisms and significance EXS 79 1997 419 428
61. W.K. You, D.M. McDonald The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis BMB Rep 41 2008 833 839
62. D.T. Aftab, D.M. McDonald MET and VEGF: synergistic targets in castration-resistant prostate cancer Clin Transl Oncol 13 2011 703 709
63. R. Du, K.V. Lu, C. Petritsch HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion Cancer Cell 13 2008 206 220 (Pubitemid 351318372)
64. B. Blouw, H. Song, T. Tihan The hypoxic response of tumors is dependent on their microenvironment Cancer Cell 4 2003 133 146 (Pubitemid 37040829)
65. National Comprehensive Cancer Network NCCN: Clinical Practice guidelines in oncology. Kidney Cancer http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#site Accessed:February 7, 2012
66. K.B. Kim, J. Chesney, D. Robinson Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma Clin Cancer Res 17 2011 7451 7461
67. H. Huynh, V.C. Ngo, J. Fargnoli Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma Clin Cancer Res 14 2008 6146 6153
68. A. du Bois, J. Huober, P. Stopfer A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies Ann Oncol 21 2010 370 375
69. P. Dubreuil, S. Letard, M. Ciufolini Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS ONE 4 2009 e7258
70. A. De Luca, N. Normanno Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors IDrugs 13 2010 636 645
71. J.M. Wood, G. Bold, E. Buchdunger PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2000 2178 2189 (Pubitemid 30225181)
72. J. Drevs, M.A. Konerding, T. Wolloscheck The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma Angiogenesis 7 2004 347 354 (Pubitemid 40767936)
73. O. Rixe, R.M. Bukowski, M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984 (Pubitemid 47629888)
74. H. van Cruijsen, E.E. Voest, C.J. Punt Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours Eur J Cancer 46 2010 901 911
75. A. Frost, M. Buechert, C. Unger Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: final results of a dose-escalation study J Clin Oncol 26 suppl 2008 abstract 2558 www.asco.org Accessed: February 7, 2012
76. C.I. Wong, T.S. Koh, R. Soo Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies J Clin Oncol 27 2009 4718 4726
77. K. Yorozuya, T. Kubota, M. Watanabe TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis Oncol Rep 14 2005 677 682
78. K. Podar, M.S. Raab, J. Zhang Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl) Blood 109 2007 1669 1677 (Pubitemid 46239601)
79. J. Matsui, Y. Yamamoto, Y. Funahashi E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition Int J Cancer 122 2008 664 671 (Pubitemid 350308963)